The "duty to warn" a patient's family members about hereditary disease risks

被引:170
作者
Offit, K
Groeger, E
Turner, S
Wadsworth, EA
Weiser, MA
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Clin Genet Serv, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Off Legal Affairs, New York, NY 10021 USA
[3] Ropes & Gray LLP, Washington, DC 20037 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2004年 / 292卷 / 12期
关键词
D O I
10.1001/jama.292.12.1469
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Genetic tests for adult-onset disorders, including common forms of cancer, are now commercially available, and tests for genetic polymorphisms that predict drug effects or toxicity after treatment are under development. For each of these circumstances, testing of 1 individual may imply an increased risk to his/her relative. The obligation, if any, to warn family members of the identification of a genetic mutation has generated concerns regarding the conflict between the physician's ethical obligations to respect the privacy of genetic information vs the potential liabilities resulting from the physician's failure to notify at-risk relatives. A duty to warn relatives about risks due to some infectious agents has been assumed by state and local health agencies, and the duty to breach confidentiality to warn of imminent harm has been the subject of case law. In general, the special nature of genetic tests has been viewed as a barrier to physicians' breaching the confidentiality of personal genetic information. However, the failure to warn family members about hereditary disease risks has already resulted in 3 lawsuits against physicians in the United States. While the findings of case law and the state and federal statutes that bear on the issue of "duty to warn" of inherited health risk are still being defined, we believe that health care professionals have a responsibility to encourage but not to coerce the sharing of genetic information in families, while respecting the boundaries imposed by the law and by the ethical practice of medicine.
引用
收藏
页码:1469 / 1473
页数:5
相关论文
共 29 条
[21]  
OFFIT K, 2004, AM SOC CLIN ONCOLOGY
[22]  
President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1998, SCREEN COUNS GEN CON
[23]   Genetic privacy [J].
Sankar, P .
ANNUAL REVIEW OF MEDICINE-SELECTED TOPICS IN THE CLINICAL SCIENCES, 2003, 54 :393-407
[24]  
Satagopan JM, 2001, CANCER EPIDEM BIOMAR, V10, P467
[25]   Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers [J].
Scheuer, L ;
Kauff, N ;
Robson, M ;
Kelly, B ;
Barakat, R ;
Satagopan, J ;
Ellis, N ;
Hensley, M ;
Boyd, J ;
Borgen, P ;
Norton, L ;
Offit, K .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1260-1268
[26]   The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis [J].
Steinbach, G ;
Lynch, PM ;
Phillips, RKS ;
Wallace, MH ;
Hawk, E ;
Gordon, GB ;
Wakabayashi, N ;
Saunders, B ;
Shen, Y ;
Fujimura, T ;
Su, LK ;
Levin, B ;
Godio, L ;
Patterson, S ;
Rodriguez-Bigas, MA ;
Jester, SL ;
King, KL ;
Schumacher, M ;
Abbruzzese, J ;
DuBois, RN ;
Hittelman, WN ;
Zimmerman, S ;
Sherman, JW ;
Kelloff, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (26) :1946-1952
[27]  
Sudell A, 2001, J Contemp Health Law Policy, V18, P273
[28]  
US Department of Health and Human Services, OCR Privacy Brief Summary of the HIPAA Privacy Rule
[29]   PREDICTIVE DNA TESTING AND PROPHYLACTIC THYROIDECTOMY IN PATIENTS AT RISK FOR MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A [J].
WELLS, SA ;
CHI, DD ;
TOSHIMA, K ;
DEHNER, LP ;
COFFIN, CM ;
DOWTON, B ;
IVANOVICH, JL ;
DEBENEDETTI, MK ;
DILLEY, WG ;
MOLEY, JF ;
NORTON, JA ;
DONISKELLER, H .
ANNALS OF SURGERY, 1994, 220 (03) :237-250